JUCHUUUUUUU morgen ...... - 500 Beiträge pro Seite

[Shun]

gehts (höchstwahrscheinlich) beim DAX bergab.

Miese Vorgaben aus Amiland.

Und ich bin nicht mehr investiert ....

Yupdididumdideldeijuminumdiedum

TIMING ist ALLES !!!!!!!!!!!

[Nachtfalkee]

selber schuld, du wirst dass beste verpassen

gruss

[Wolfgang7]

@Nachtfalkee

[Ariminios]

jetzt johl mal nicht, die Amis sind ja grad mal ein Prozent runter

[Nachtfalkee]

@wolfgang

abwarten

[Wolfgang7]

@Nachtfalkee

Mob

[liebemachtblind]

ich bin sogar short geblieben
andy

[Watcher42]

Auch Leute mit PUT´s kommen böse unter die Räder.

Und Leute die sich auf fallende Kurse freuen kann ich nicht ausstehen.

mfg

[Nachtfalkee]

warte auf die qiagen zahlen,und vertreibe mir die zeit mit ein wenig kommunikation.

[Wolfgang7]

Sieht doch gut aus, oder??!!!!!!!!

[Nachtfalkee]

schau mer mal

[williaktie]

vergesst es,fallende Kurse gibt es " nicht mehr" vorerst.
Dax Morgen 3300.
ein Tip, Schering,kaufen
mfg

[Nachtfalkee]

bis ende jahr bin ich auch positiv gestimmt

[Quasselkasper]

[liebemachtblind]

gegenargument
das wird ein katzenpuckel
andy

[Nachtfalkee]

bitte übersetzen

MONDAY, OCTOBER 28, 2002 4:23 PM
- PR Newswire

VENLO, The Netherlands, Oct 28, 2002 /PRNewswire-FirstCall via COMTEX/ -- QIAGEN N.V. (Nasdaq: QGENF, Neuer Markt: QIA) today announced the results of operations for its third quarter and nine-month period ended September 30, 2002.

The Company reported that consolidated net sales for its third quarter increased 21% to $76.9 million, from $63.3 million for the same period in 2001. Operating income increased 28% to $12.9 million from $10.1 million in the comparable period in 2001, net income increased 18% to $7.3 million from $6.2 million in the same quarter of 2001 and diluted earnings per share increased 25% to $0.05 (based on 146.0 million average shares and share equivalents outstanding) from $0.04 (based on 144.9 million average shares and share equivalents outstanding).

The reported consolidated net sales were higher than and diluted earnings per share were in line with the Company`s guidance for the third quarter as communicated on July 3, 2002.

For the nine-month period ended September 30, 2002, total reported net sales increased 14% to $220.2 million from $192.5 million in the comparable period of 2001. Excluding the effect of one-time charges related to the acquisition of GenoVision AS during the second quarter 2002 as well as related to the acquisition of the SAWADY group during the first quarter of 2001 and a gain on the sale of a financial asset of approximately $1.4 million during the second quarter of 2001, operating income for the nine-month period ended September 30, 2002 increased 4% to $40.9 million from $39.3 million in 2001 and net income decreased 2% to $23.6 million in 2002 from $24.1 million in 2001 and diluted earnings per share decreased 6% to $0.16 from $0.17. Reported operating income, which was negatively impacted by one-time charges and the Company`s financial performance in the second quarter of 2002, increased 5% to $38.0 million from $36.3 million in the comparable period in 2001, net income decreased 9% to $21.4 million from $23.5 million in the first nine-months of 2001, and diluted earnings per share decreased 6% to $0,15 (based on 145.8 million average shares and share equivalents) from $0,16 (based on 145.0 million average shares and share equivalents).

"We are pleased to have achieved significant revenue growth during this third quarter of 2002," said Dr. Metin Colpan, QIAGEN`s Chief Executive Officer. "Our core consumable products for the separation, purification and handling of nucleic acids represented approximately 72% of consolidated net sales and showed strong growth of approximately 24%. Academic, pharmaceutical and biotech markets for these products all continued to show strong increases in demand. Our synthetic nucleic acid business contributed approximately 13% of net sales. We met our targets in this third quarter in this business and remain optimistic about opportunities in profitable segments, however, the synthetic nucleic acid business continues to perform below the profitability and growth expectations we set for our businesses in general. The instrumentation business represented approximately 10% of net sales and experienced a growth rate of 7% compared to the second quarter 2002. QIAGEN launched a series of exciting new automation products in this third quarter such as the BioRobot MDx targeting clinical customers as well as the BioRobot M product lines. We believe that these products have the potential to contribute to significant growth in future periods. With its unique and highly focused portfolio addressing more than 80 different applications in nucleic acid handling, separation and purification, QIAGEN is well positioned to take full advantage of the accelerating momentum in the life science industry."

INLINE oder ??????????????????

[Wolfgang7]

MONTAG, DER 28. OKTOBER 2002 4:23 NACHMITTAGS - PR Newswire VENLO, Die Niederlande, am 28. Okt 2002/PRNewswire-FirstCall durch COMTEX/-QIAGEN N.V. (Nasdaq: QGENF, Neuer Markt: QIA) kündigte heute die Resultate von Betrieben für sein drittes Viertel und neunmonatige am 30. September 2002 beendete Periode an. Die Firma berichtete, dass sich festigte, vergrößerten Nettoverkäufe für sein drittes Viertel 21 % zu 76.9 Millionen $, von 63.3 Millionen $ für die gleiche Periode 2001. Betriebseinkommen vergrößerte 28 % zu 12.9 Millionen $ von 10.1 Millionen $ in der vergleichbaren Periode 2001, Nettoeinkommen vergrößerte 18 % zu 7.3 Millionen $ von 6.2 Millionen $ im gleichen Viertel von 2001 und verdünnte Verdienst per Anteil vergrößerte 25 % zu 0.05 $ (gegründet auf 146.0 Millionen durchschnittlichen Anteilen und hervorragendem Aktiengegenwert) von 0.04 $ (gegründet auf 144.9 Millionen durchschnittlichen Anteilen und hervorragendem Aktiengegenwert). Die berichteten festen Nettoverkäufe waren höher als und verdünnten Verdienst per Anteil waren mit der Firma ` s Führung für das dritte Viertel wie mitgeteilt am 3. Juli 2002 im Einklang.




hier ein link!!!
http://reversonet.lycos.de/translator.asp

[Quasselkasper]

@liebemachtblind
Die "Katzenbuckel"-Formation ist mir leider nicht geläufig. Könntest du dies bitte näher erläutern?

Gruss,
Quassel

[Nachtfalkee]

@wolfgang

klasse und vielen dank

gruss NF

[Wolfgang7]

bitte gerne